Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

20 Oct 2016
Detection of Acute and Early HIV-1 Infections in an HIV Hyper-Endemic Area with Limited Resources.
Mayaphi SH, Martin DJ, Quinn TC, Laeyendecker O, Olorunju SA, Tintinger GR, Stoltz AC.
PLoS One, 2016: 11(10): e0164943, 10.1371/journal.pone.0164943
Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study.
Solomon SS, Mehta SH, McFall AM, Srikrishnan AK, Saravanan S, Laeyendecker O, Balakrishnan P, Celentano DD, Solomon S, Lucas GM.
Lancet HIV, 2016: 3(4): e183-90., 10.1016/S2352-3018(16)00019-9
Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
Kirkpatrick AR, Patel EU, Celum CL, Moore RD, Blankson JN, Mehta SH, Kirk GD, Margolick JB, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS Res Hum Retroviruses, 2016: 32(8): 756-762, doi: 10.1089/AID.2015.0198.
Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.
Patel EU, Cox AL, Mehta SH, Boon D, Mullis CE, Astemborski J, Osburn WO, Quinn J, Redd AD, Kirk GD, Thomas DL, Quinn TC, Laeyendecker O.
J Infect Dis, 2016: 214(3): 344-352, 10.1093/infdis/jiw005
Improvements in the continuum of HIV care in an inner-city emergency department.
Kelen GD, Hsieh YH, Rothman RE, Patel EU, Laeyendecker OB, Marzinke MA, Clarke W, Parsons T, Manucci JL, Quinn TC.
AIDS, 2016: 30(1): 113-120, 10.1097/QAD.0000000000000896
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction.
Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, Singer J, Pankovich J, Laeyendecker O, Kaul R, Kandel G, Kovacs C.
Open Forum Infect Dis, 2015: 2(4): ofv138, 10.1093/ofid/ofv138.
Short Communication: Low False Recent Rate of Limiting-Antigen Avidity Assay Among Long-Term Infected Subjects from Guangxi, China.
Yu L, Laeyendecker O, Wendel SK, Liang F, Liu W, Wang X, Wang L, Pang X, Fang Z.
AIDS Res Hum Retroviruses, 2015: 31(12): 1247-1249, 10.1089/aid.2015.0097
High HIV prevalence and incidence among MSM across 12 cities in India.
Solomon SS, Mehta SH, Srikrishnan AK, Vasudevan CK, Mcfall AM, Balakrishnan P, Anand S, Nandagopal P, Ogburn EL, Laeyendecker O, Lucas GM, Solomon S, Celentano DD.
AIDS, 2015: 29(6): 723-731, 10.1097/QAD.0000000000000602

Pages

  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Contact

Tel: xxx-xxx-xxxx

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Amy Wesolowski
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6516
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2022 Infectious Disease Dynamics
Website by Manta Ray Media